CELLECTIS S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.66 EUR | +0.57% |
|
-0.75% | -3.76% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 16.19M 17.58M 23.96M | Sales 2025 * | 70.57M 76.63M 104M | Capitalization | 191M 207M 282M |
|---|---|---|---|---|---|
| Net income 2024 * | -74M -80.35M -109M | Net income 2025 * | -71M -77.09M -105M | EV / Sales 2024 * | 11.8 x |
| Net cash position 2024 * | 573K 622K 848K | Net cash position 2025 * | 180M 195M 266M | EV / Sales 2025 * | 0.16 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 219 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cellectis S.A.
More recommendations
More press releases
| 1 day | +0.57% | ||
| 1 week | -0.75% | ||
| Current month | +9.24% | ||
| 1 month | +11.30% | ||
| 3 months | +7.17% | ||
| 6 months | +2.31% | ||
| Current year | -3.76% |
1 week
2.62
2.83
1 month
2.323.03
Current year
2.133.03
1 year
0.893.44
3 years
0.8913.81
5 years
0.8928.45
10 years
0.8941.95
| Managers | Title | Age | Since |
|---|---|---|---|
David Sourdive
FOU | Founder | 57 | 99-12-19 |
André Choulika
FOU | Founder | 59 | 99-12-19 |
Arthur Stril
DFI | Director of Finance/CFO | 35 | 18-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 75 | 20-11-04 | |
André Choulika
FOU | Founder | 59 | 99-12-19 |
David Sourdive
FOU | Founder | 57 | 99-12-19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-20 | 2.66 | +0.57% | 39,221 |
| 24-05-17 | 2.645 | -3.11% | 69,739 |
| 24-05-16 | 2.73 | -1.09% | 28,892 |
| 24-05-15 | 2.76 | +1.66% | 86,400 |
| 24-05-14 | 2.715 | +1.31% | 73,325 |
Real-time Euronext Paris, May 20, 2024 at 11:35 am
More quotes
Cellectis S.A. is a clinical-stage biotechnology company using its pioneering TALEN® genome-editing technology to develop innovative therapies for the treatment of serious diseases. Cellectis S.A. is developing the first CAR-T cell-based allogeneic immunotherapy therapeutics, inventing the concept of off-the-shelf, ready-to-use engineered CAR-T cells for the treatment of cancer patients, and a platform for performing therapeutic genetic modifications in hematopoietic stem cells in a various diseases. Capitalizing on its 23 years of expertise in genome engineering, its TALEN® genome editing technology and its pioneering PulseAgile electroporation technology, Cellectis S.A. is developing innovative product candidates using the power of the immune system to treat diseases with unmet medical needs. As part of its commitment to the search for curative cancer therapies, Cellectis S.A. is developing UCART product candidates directed at the unmet medical needs of patients with certain types of cancer, including acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and multiple myeloma. HEAL is a new platform focused on hematopoietic stem cells for the treatment of blood disorders, immune deficiencies, and lysosomal storage diseases.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
C
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -3.76% | 206M | |
| +41.79% | 50.93B | |
| -0.56% | 42.12B | |
| +49.62% | 42.05B | |
| -7.20% | 29.18B | |
| +12.59% | 26.02B | |
| -21.51% | 18.9B | |
| +6.92% | 13.21B | |
| +24.91% | 12.17B | |
| +29.60% | 12.16B |
- Stock Market
- Equities
- ALCLS Stock
